{
    "article_link": "https://doi.org/10.1038/s41467-023-42565-z",
    "data": [
        {
            "id": "data_1",
            "omics": "Epigenomics",
            "link": "https://ngdc.cncb.ac.cn/gsa-human/",
            "format": "BAM (raw reads) and BED (processed ACRs)",
            "source": "Genome Sequence Archive for Human (GSA-human)",
            "public_id": "HRA002815"
        },
        {
            "id": "data_2",
            "omics": "Transcriptomics",
            "link": "https://ngdc.cncb.ac.cn/gsa-human/",
            "format": "BAM",
            "source": "Genome Sequence Archive for Human (GSA-human)",
            "public_id": "HRA000119"
        },
        {
            "id": "data_3",
            "omics": "Genomics (Whole Genome Sequencing)",
            "link": "https://ngdc.cncb.ac.cn/gsa-human/",
            "format": "BAM",
            "source": "Genome Sequence Archive for Human (GSA-human)",
            "public_id": "HRA002815 (diagnosis-remission-relapse trios)"
        },
        {
            "id": "data_4",
            "omics": "Epigenomics (ATAC-seq)",
            "link": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122989",
            "format": "BAM",
            "source": "Gene Expression Omnibus (GEO)",
            "public_id": "GSE122989"
        },
        {
            "id": "data_5",
            "omics": "Chromatin Immunoprecipitation Sequencing (ChIP-seq)",
            "link": "https://ega-archive.org/",
            "format": "BAM",
            "source": "European Genome-phenome Archive (EGA)",
            "public_id": "EGAD00001002421"
        },
        {
            "id": "data_6",
            "omics": "Transcriptomics",
            "link": "https://depmap.org/portal/download",
            "format": "Processed Data",
            "source": "DepMap",
            "public_id": "DepMap Public 21Q1"
        },
        {
            "id": "data_7",
            "omics": "Drug Response",
            "link": "https://depmap.org/portal/download",
            "format": "AUC (Processed Data)",
            "source": "Cancer Therapeutics Response Database (CTD^2)",
            "public_id": "Drug Sensitivity AUC (CTD^2)"
        },
        {
            "id": "data_8",
            "omics": "Genomics/Transcriptomics",
            "link": "https://gdc.cancer.gov/about-data/publications#/?groups=TARGET-ALL-P2&years=&order=desc",
            "format": "Processed Data",
            "source": "TARGET",
            "public_id": "phs000464"
        }
    ],
    "analyses": [
        {
            "id": "analysis_1",
            "analysis_name": "Chromatin Accessibility Landscape",
            "analysis_data": [
                "data_1"
            ],
            "label": null
        },
        {
            "id": "analysis_2",
            "analysis_name": "Comparison with B-cell Progenitors",
            "analysis_data": [
                "data_1",
                "data_4"
            ],
            "label": null
        },
        {
            "id": "analysis_3",
            "analysis_name": "Subtype-specific Chromatin Accessibility",
            "analysis_data": [
                "data_1"
            ],
            "label": null
        },
        {
            "id": "analysis_4",
            "analysis_name": "Allele-specific Open Chromatin (ASOC) Analysis",
            "analysis_data": [
                "data_1",
                "data_3"
            ],
            "label": null
        },
        {
            "id": "analysis_5",
            "analysis_name": "Differential Chromatin Accessibility Between Diagnosis and Relapse",
            "analysis_data": [
                "data_1",
                "data_3"
            ],
            "label": {
                "condition": [
                    "Diagnosis",
                    "Relapse"
                ],
                "subtypes": [
                    "BCR::ABL1",
                    "BCR::ABL1-like",
                    "ETV6::RUNX1",
                    "Hyperdiploidy"
                ]
            }
        },
        {
            "id": "analysis_6",
            "analysis_name": "Relapse-free Survival (RFS) Analysis",
            "analysis_data": [
                "data_1",
                "data_8"
            ],
            "label": {
                "group": [
                    "Group A",
                    "Group B"
                ]
            }
        },
        {
            "id": "analysis_7",
            "analysis_name": "ACR-to-Gene Association",
            "analysis_data": [
                "data_1",
                "data_2"
            ],
            "label": null
        },
        {
            "id": "analysis_8",
            "analysis_name": "Drug Response Gene Enrichment",
            "analysis_data": [
                "data_6",
                "data_7"
            ],
            "label": {
                "drug": [
                    "Cyclophosphamide",
                    "Cytarabine",
                    "Dasatinib",
                    "Dexamethasone",
                    "Doxorubicin",
                    "Etoposide",
                    "Imatinib",
                    "Methotrexate"
                ]
            }
        },
        {
            "id": "analysis_9",
            "analysis_name": "Transcription Factor Motif Analysis",
            "analysis_data": [
                "data_1",
                "data_2"
            ],
            "label": null
        },
        {
            "id": "analysis_10",
            "analysis_name": "Survival Analysis",
            "analysis_data": [
                "data_1",
                "data_8"
            ],
            "label": null
        },
        {
            "id": "analysis_11",
            "analysis_name": "Unsupervised Clustering of Transcription Factors",
            "analysis_data": [
                "data_1",
                "data_2"
            ],
            "label": {
                "cluster_group": [
                    "Cluster 1",
                    "Cluster 2",
                    "Cluster 3"
                ]
            }
        },
        {
            "id": "analysis_12",
            "analysis_name": "Survival Analysis by Subtypes",
            "analysis_data": [
                "data_1",
                "data_8"
            ],
            "label": {
                "group": [
                    "Group A",
                    "Group B"
                ]
            }
        },
        {
            "id": "analysis_13",
            "analysis_name": "Diagnosis-Relapse Chromatin Accessibility Comparison",
            "analysis_data": [
                "data_1",
                "data_3"
            ],
            "label": {
                "time_points": [
                    "Diagnosis",
                    "Relapse"
                ]
            }
        },
        {
            "id": "analysis_14",
            "analysis_name": "Quies ACRs and H3K27ac Overlap",
            "analysis_data": [
                "data_1",
                "data_5"
            ],
            "label": null
        }
    ],
    "results": [
        {
            "analysis_id": "analysis_1",
            "metrics": "Number of ACRs",
            "value": "138,366 (median), ranging from 57,941 to 204,563",
            "features": []
        },
        {
            "analysis_id": "analysis_2",
            "metrics": "Overlap with B-cell Progenitor ACRs",
            "value": "98.57% (pre-pro B cells), 98.35% (pro B cells)",
            "features": [
                "IL7R",
                "TCL1A",
                "TCF3",
                "RHOA",
                "ELL",
                "MYC"
            ]
        },
        {
            "analysis_id": "analysis_3",
            "metrics": "Subtype-specific ACRs",
            "value": "17,981 subtype-specific ACRs identified",
            "features": [
                "ETV6::RUNX1",
                "TCF3::PBX1",
                "Hyperdiploidy",
                "KMT2A",
                "BCR::ABL1",
                "BCR::ABL1-like",
                "ZNF384",
                "PAX5alt",
                "TCF3::HLF",
                "Hypodiploidy",
                "MEF2D",
                "B-other"
            ]
        },
        {
            "analysis_id": "analysis_4",
            "metrics": "Percentage of ASOC regions",
            "value": "14.39% (median), significantly less than BiOC regions (85.61%)",
            "features": [
                "ARID5B",
                "BCL2L11",
                "MECOM",
                "HOXA9"
            ]
        },
        {
            "analysis_id": "analysis_5",
            "metrics": "Number of differential ACRs",
            "value": "5911 relapse-high ACRs (0.95%), 1423 relapse-low ACRs (0.23%)",
            "features": [
                "MYC",
                "E2F6"
            ]
        },
        {
            "analysis_id": "analysis_6",
            "metrics": "Number of RFS-related ACRs",
            "value": "70,573 ACRs (11.29% of 625,287 recurrent c-ACRs)",
            "features": [
                "Cell cycle-related genes",
                "Leukocyte differentiation-associated genes",
                "Group A (better prognosis)",
                "Group B (inferior prognosis)",
                "Hyperdiploidy cases split into two groups"
            ]
        },
        {
            "analysis_id": "analysis_7",
            "metrics": "Number of ACR-gene correlations",
            "value": "116,307 ACR-gene correlations identified (|log2FC| > 1, FDR < 0.05)",
            "features": [
                "1259 potential target genes",
                "Actin cytoskeleton organization",
                "Cell adhesion/migration-related processes",
                "Drug response genes"
            ]
        },
        {
            "analysis_id": "analysis_8",
            "metrics": "Enrichment in drug response genes",
            "value": "Significant enrichment for Cyclophosphamide (p = 0.0029), Cytarabine (p = 0.0184), Dasatinib (p = 0.0178), Doxorubicin (p = 0.0167)",
            "features": [
                "Cell adhesion/migration-related genes",
                "Drug response genes"
            ]
        },
        {
            "analysis_id": "analysis_9",
            "metrics": "Number of TFs associated",
            "value": "109 TFs associated with subtype-specific ACRs",
            "features": [
                "E2F6 (ETV6::RUNX1-specific)",
                "RUNX1",
                "ZFP82",
                "SPI1",
                "KLF9",
                "NRF1",
                "RARG",
                "SALL4",
                "CTCF"
            ]
        },
        {
            "analysis_id": "analysis_10",
            "metrics": "Event-free survival (EFS) and Overall survival (OS)",
            "value": "EFS p = 0.0012, OS p = 0.0002 (Fig. 5g)",
            "features": [
                "Cluster 3 (worst prognosis)",
                "Hyperdiploidy cases in Group B",
                "ETV6::RUNX1 in Group A"
            ]
        },
        {
            "analysis_id": "analysis_11",
            "metrics": "Transcription factor clustering",
            "value": "109 TFs grouped into 9 clusters",
            "features": [
                "9 clusters of TFs",
                "ETV6::RUNX1-specific cluster (E2F6)",
                "Shared clusters (e.g., KMT2A/ZNF384, BCR::ABL1/BCR::ABL1-like)"
            ]
        },
        {
            "analysis_id": "analysis_12",
            "metrics": "Proportion of RFS-related ACRs",
            "value": "11.29% (70,573 out of 625,287 recurrent c-ACRs)",
            "features": [
                "Hyperdiploidy cases in Group B",
                "Cluster 3 (hyperdiploidy, worst prognosis)",
                "ETV6::RUNX1 in Group A"
            ]
        },
        {
            "analysis_id": "analysis_13",
            "metrics": "Clonal evolution patterns",
            "value": "3156 differential ACRs identified between hyperdiploidy subgroups (|log2FC| > 1, FDR < 0.05)",
            "features": [
                "3156 ACRs with increased accessibility in Group B hyperdiploidy",
                "603 potential target genes",
                "Stem cell/myeloid progenitor-like signatures"
            ]
        },
        {
            "analysis_id": "analysis_14",
            "metrics": "Quies ACRs and H3K27ac overlap",
            "value": "64.83% of Quies ACRs located in gene regions (Â±5% gene length)",
            "features": [
                "64.83% gene region overlap",
                "70.59% H3K27ac signal overlap"
            ]
        }
    ]
}